Nothing, in law. The phrase shows up zero times in the federal drug rules. The words that do carry weight are USP and GMP, and almost nothing on a peptide site has either one.
A reader asked a fair question about a product page that promised pharmaceutical grade material alongside a certificate showing 99.2% purity. The two claims look like they belong together. They are doing completely different work, and only one of them points at anything a buyer can check.
Is "pharmaceutical grade" defined anywhere in US drug law?
No. The phrase does not appear in Title 21 of the Code of Federal Regulations. That is where every FDA drug regulation lives.
That is a countable claim, so it can be counted. A full-text search of Title 21 run on October 21, 2026 returns the following.1 Figures below were checked that day.
| Phrase | Times it appears in 21 CFR | What it refers to there |
|---|---|---|
| Current good manufacturing practice | 1,354 | A regulated manufacturing system, defined across multiple parts |
| United States Pharmacopeia | 59 | The official compendium, named in labeling and standards rules |
| Official compendium | 23 | USP, the National Formulary and the Homeopathic Pharmacopoeia |
| Medical grade | 4 | Device materials only: silicone elastomer, acrylic adhesive |
| Pharmaceutical grade | 0 | Nothing |
| Research grade | 0 | Nothing |
The control matters here, because a search returning zero can mean the search is broken. "Current good manufacturing practice" returned 1,354 hits from the same query against the same database, so the endpoint works and the zero is a zero.
"Medical grade" is the interesting middle case. It survives in four places, and in all four it describes what a device part is made from, never a tier of drug quality.
What quality terms does the law actually define?
Three terms do the work that the marketing phrase only gestures at.
The first is the official compendium. The Federal Food, Drug and Cosmetic Act defines it as the United States Pharmacopeia, the National Formulary and the Homeopathic Pharmacopoeia. The second is good manufacturing practice, a system of controls over how a drug is made. The third is the monograph, a published document setting the tests, methods and acceptance limits for one named substance.
None of these is a grade in the sense a product page uses the word. They are not tiers on a ladder. Each one is a specific document or a specific inspection, and a product either conforms to it or does not.
Set the defined terms beside the marketing ones and the difference is easy to see.
| Term | Where it is defined | What it applies to | Can a buyer verify it? |
|---|---|---|---|
| USP | A published monograph in the USP-NF, recognized by the Food, Drug and Cosmetic Act2 | One named substance, where a monograph exists | Yes, by reading the monograph |
| GMP, meaning cGMP for a finished medicine | 21 CFR Part 211, a regulation3 | Finished dosage forms made for people or animals | Partly, through FDA inspection records |
| cGMP for a bulk ingredient | ICH Q7, an FDA guidance that is not binding4 | Active pharmaceutical ingredients, from the defined starting material onward | Rarely, and only with facility documents |
| Pharmaceutical grade, or pharma grade | Nowhere in 21 CFR1 | Undefined | No |
| Research grade | Nowhere in 21 CFR1 | Undefined | No |
| Medical grade | 21 CFR, four times, all for device materials1 | Silicone elastomer and adhesives in devices | Not applicable to a peptide |
The two rows at the bottom are the ones that appear most often on product pages, and they are the two with nothing in the middle columns.
What does "USP" on a label actually mean?
It means the product claims to meet a named monograph. A product that misses the monograph can be seized.
Section 351(b) of the Act is the machinery. A drug represented as a substance whose name is recognized in an official compendium is deemed adulterated if "its strength differs from, or its quality or purity falls below, the standard set forth in such compendium."2 Strength, quality and purity are judged by the compendium's own tests. If those tests are missing or inadequate, the Secretary must notify the body that revises the compendium, and must write the tests by regulation if that body does not act.2
One escape exists, and it explains some labeling you will see. A drug that differs from the compendial standard is not adulterated on that basis if the difference is "plainly stated on its label."2 You can sell something that misses the monograph. You cannot sell it quietly.
That is the whole difference between a defined term and a marketing one. "USP" points at a document with numbers in it, written by a body outside the seller, enforceable by a statute. "Pharmaceutical grade" points at the seller's own opinion of the seller.
Do the peptides people buy have a USP standard at all?
Rarely. For most of what sells on these sites, that single fact settles the question.
USP publishes peptide standards for sixteen peptide families: bivalirudin, salmon calcitonin, corticotropin, cosyntropin, desmopressin, eptifibatide, exenatide, glucagon, gonadorelin, leuprolide, octreotide, oxytocin, protamine sulfate, teriparatide, triptorelin and vasopressin.5 Each family carries documentary standards with validated test methods and acceptance criteria, plus reference standards for the substance and its known impurities.5
Our October 21, 2026 price capture holds 14,492 listings across 206 sellers, covering 192 distinct compounds. Cross the two lists and four compounds match: gonadorelin, oxytocin, teriparatide and triptorelin.6 Those four account for 179 listings.
So about one listing in a hundred is for a compound that has a compendial standard to be measured against. For the other 188 compounds there is no monograph, no published acceptance limit, and nothing for the words "USP grade" to refer to even if a seller used them.
This is not a gap in enforcement. It is a gap in the existence of a standard. Nobody has written one, because writing a monograph is work that follows a drug into regulated use, and most of these compounds have not gone there.
What does good manufacturing practice require that a certificate does not?
A certificate describes one sample. Good manufacturing practice describes the place that produced it.
Part 211 of Title 21 sets that system out in eleven subparts and sixty sections, running from the building and the equipment through component control, production, packaging, holding, laboratory controls and records.3 The subject is never a single test result. It is whether the place that made the material is organized so that results mean something.
One section carries most of the weight. Every operation has to run a quality control unit, and that unit holds the power to reject anything in the building: the raw components, the containers and closures, the in-process material, the packaging, the labeling, and the finished product.7 It reviews the production records to confirm no errors crept in, and where they did, it has to see them investigated through to an answer before anything moves. It keeps laboratory facilities of its own. Its responsibilities "shall be in writing," and those written procedures "shall be followed."7
Read that against what arrives in a padded envelope. A certificate is a measurement of a sample at a moment. A quality system is a standing arrangement with the authority to reject, an investigation trail, and an inspector who can walk in and read the records. The first can be real and the second absent, and that combination is most of this market.
I want to give the seller's side of this properly, because the phrase is not always empty. Some sellers do buy from manufacturers running genuine quality systems, and when they say pharmaceutical grade they may be pointing at something true about the factory. The trouble is twofold. You cannot check it, and whatever system existed upstream usually stops at the point where bulk material is repackaged into vials by someone else.
Does GMP mean the same thing for a bulk peptide as for a medicine?
No. The two standards are different documents carrying different force.
Part 211 governs drug products, and the regulations define a drug product as "a finished dosage form, for example, tablet, capsule, solution, etc."8 The bulk peptide a synthesis house ships by the kilogram is not that. It is an active pharmaceutical ingredient, and the standard FDA applies to it is ICH Q7, issued as a guidance for industry in its 2016 revision and covering APIs made by chemical synthesis among other routes.4
Two differences follow and both matter. Q7 is a guidance, so every page of it carries the line "Contains Nonbinding Recommendations," and the document says in terms that it is not binding on FDA or on the public.4 Part 211 is a regulation with the force of law behind it. A seller saying GMP could be pointing at either one, and the two are not the same instrument.
The second difference is where the coverage starts. Q7 asks a company to document the point at which API production begins, and for a synthetic process that point is where the defined starting material enters.4 Everything before it sits outside the guidance entirely. So even a genuine Q7 claim describes a window in a process, not the whole history of the powder.
Is there anything about a manufacturer you can actually look up?
One record is public: the list of drug establishments registered with FDA.
Establishments that make or process drugs distributed in the United States have to register with FDA, and the current list is published as the Drug Establishments Current Registration Site, updated every business day.9 If a seller names the facility behind its material, you can check whether that facility appears.
Read the result carefully in both directions. Registration is a filing requirement with a deadline, five days from starting operations and an annual renewal window, and 21 CFR 207.77 says in terms that "Registration of an establishment or listing of a drug does not denote approval of the establishment, the drug."10 A registered facility has filed a form, and a filed form opens a question instead of closing one.
An absence tells you more than a presence. A seller naming a manufacturer that does not appear on a list updated daily has given you something specific and checkable that did not check out. That is a different quality of information from an adjective.
How pure does a drug-grade peptide actually have to be?
The published thresholds are tighter than a 99% certificate suggests.
FDA's May 2021 guidance for generic versions of five synthetic peptides sets the numbers.11 Applicants "should identify each peptide-related impurity that is 0.10 percent of the drug substance or greater," and anything between 0.10% and 0.5% needs structural characterization.11 A new impurity not present in the reference drug should be "no more than 0.5 percent of the drug substance," above which the guidance says the generic pathway may not be appropriate at all.11
Hold those two figures next to a purity claim. A vial certified at 99.0% has 1% that is something else. That is ten times the level at which a regulated applicant would have to name each impurity and work out its structure, and twice the ceiling for any single new one.
The reason is not fussiness. Peptide-related impurities are near-copies of the target molecule, and the guidance is explicit that they carry "the potential for differences in immunogenicity" against the reference product.11 An applicant has to show an impurity does not carry sequences with increased affinity for MHC, does not raise aggregation, and does not stimulate innate immune activity more than the reference does.11
None of that is on a purity certificate. A purity figure tells you how much of the peptide material is the one you wanted. It does not tell you what the rest is, and the published standard treats the rest as the interesting part.
Does a 99% certificate make a vial pharmaceutical grade?
No. The two are not measuring the same kind of thing.
Purity is a share of peptide material. Grade, in the only sense the law recognizes, is a property of a manufacturing system under inspection. A number on a page cannot establish a system, and a system does not produce a grade label.
A second gap sits underneath this one. A purity percentage is not even a statement about what is in the vial by weight. Our guide on what a peptide purity number actually measures works through counterion and water content and why a 99% certificate routinely sits on a powder that is well under 99% peptide. That is a separate problem from the grade claim, and it compounds it.
What does the phrase do legally when a seller uses it?
Used carelessly it can work against the seller. Most buyers never hear that part.
Intended use under 21 CFR 201.128 turns on the objective intent of whoever is legally responsible for an article's labeling. That intent can be shown by "labeling claims, advertising matter, or oral or written statements."12 A seller's own words are the evidence.
So a page carrying both a research use only disclaimer and a promise of pharmaceutical grade quality is doing two incompatible things at once. The disclaimer says this is not for people. The grade claim describes a standard that exists only because drugs go into people. Our guide on what research use only actually means covers how that tension is read.
For the buyer the practical consequence is smaller and more immediate. A vague grade claim will not support a payment dispute, because there is no definition to breach. A stated purity figure, a named compound and a lot number will, because each of those is specific enough to be wrong. Our guide on what to do when an order arrives wrong turns on exactly that distinction.
What do the stores actually show?
Most of them show less than their copy claims. We audited that instead of guessing.
As of October 21, 2026 the site tracks 206 stores, of which 183 carry a testing score.13 Each is scored against five things a reader can verify: whether the store names its testing lab, whether a certificate can be matched to a lot number, whether HPLC is named as the purity method, whether mass spectrometry is named for identity, and whether the testing is independent. Twenty-three stores meet all five.13
The scoring rule is the point. A criterion counts only where a store shows something checkable, a lot number, a dated certificate, a method named on a document. A claim alone lights nothing, however confidently it is worded.13 "Pharmaceutical grade" is not one of the five criteria and could not be, since there is no document it would correspond to.
One store in that audit put the same lot number on certificate files for eight different products.13 Every one of those files was a real document with a real number on it. The failure mode to carry away is that one: the problem is rarely an absence of paperwork.
What can you check instead?
The useful questions all end in a document instead of an adjective. There are four of them.
Ask for the certificate of analysis for your lot, with the lot number on the vial matching the number on the COA. A certificate for a different lot describes a different material, however good its numbers look.
Ask which method produced the purity figure and which produced the identity result. HPLC gives you purity, mass spectrometry gives you identity, and a certificate naming neither has told you nothing you can repeat.
Ask who ran it. A named laboratory with an accreditation number is checkable. "Third party tested" is not a party.
Ask for counterion and moisture figures, or a net peptide content number, if you want to know what is in the vial by weight rather than what share of the peptide is the right peptide.
Then treat the grade claim as what it is, a sentence the seller wrote about themselves. It is not evidence and it is not a lie. It is simply not a thing anyone has defined. The stores with the most to show tend not to lean on it.
Common questions
Is "pharmaceutical grade" a legal term in the United States?
No. The phrase appears zero times in Title 21 of the Code of Federal Regulations, the title holding the FDA's drug regulations. A control search for "current good manufacturing practice" in the same database returned 1,354 hits, so the zero is not a broken search.
Pharmaceutical grade vs USP grade: which one means something?
USP grade, where a monograph exists for that substance. It names a published document with tests and limits in it, and federal law treats a drug falling below that standard as adulterated. Pharmaceutical grade and pharma grade name nothing at all, and neither appears anywhere in the drug regulations.
What is the difference between USP grade and pharmaceutical grade?
USP points at a published monograph with specific tests and limits for one named substance, and a drug that falls below it is deemed adulterated under federal law. Pharmaceutical grade points at nothing published. Only one of the two can be looked up.
Does a peptide with a USP monograph exist on peptide websites?
Occasionally. USP publishes peptide standards for sixteen families, and four of them appear among the 192 compounds in our October 2026 price capture: gonadorelin, oxytocin, teriparatide and triptorelin. Those four account for 179 of 14,492 listings.
If there is no USP monograph, can anything be pharmaceutical grade?
Not in any checkable sense. Where no compendial standard exists for a substance, there is no published specification to conform to, so a grade claim about it cannot be verified or falsified by anyone.
Is GMP the same as pharmaceutical grade?
No. Good manufacturing practice is a regulated system covering the building, the equipment, component control, production, records and a quality unit with authority to reject. It describes how material is made, not a quality tier a finished vial can be assigned.
Can a certificate of analysis prove something is pharmaceutical grade?
No. A certificate reports tests on a sample. Manufacturing practice is a standing system that an inspector verifies, including written procedures that must be followed and an investigation trail for errors. One cannot establish the other.
Is 99% purity good enough to count as drug quality?
Not by the published standard. FDA guidance for generic synthetic peptides asks applicants to identify each peptide-related impurity at 0.10% or above, and caps any new impurity at 0.5%. A 99% certificate leaves 1% unidentified, ten times the identification threshold.
Why does the remaining 1% matter so much?
Peptide impurities are near-copies of the target molecule. FDA's guidance says they carry potential differences in immunogenicity, and asks applicants to show an impurity does not increase MHC affinity, aggregation or innate immune stimulation. A purity number says nothing about any of that.
Does "pharmaceutical grade" mean a peptide is sterile?
No. Sterility is a separate test, and so is endotoxin. Neither is implied by a grade claim, a purity figure or an identity result.
Does the phrase mean the seller is breaking the law?
Not on its own. The phrase is undefined, not prohibited. What it can do is contribute to intended use under 21 CFR 201.128, determined from a seller's own labeling claims and written statements. That sits awkwardly beside a research use only disclaimer on the same page.
Can I dispute a payment because the product was not pharmaceutical grade?
That claim is very hard to run, because there is no definition for the seller to have breached. A stated purity figure, a named compound or a lot number that does not match is far stronger, since each one is specific enough to be shown wrong.
What should I ask a seller instead?
The certificate for your lot with the lot number matching the vial, the method behind the purity figure, the method behind the identity result, the name of the laboratory that ran them, and counterion or moisture figures if you want to know what is in the vial by weight.
Does "third party tested" mean anything?
Only that someone outside the seller ran a test. It does not say which lab, which method, which lot, or what the result was. A named laboratory with an accreditation number on a dated certificate is the checkable version of that claim.
How many stores actually publish checkable testing?
Of 206 stores tracked as of October 21, 2026, 183 carry a score against five criteria, and 23 meet all five. A criterion counts only where the store shows something verifiable, never on a claim alone.
Do certificates ever look right and still be wrong?
Yes. One store in our audit used the same lot number on certificate files for eight different products. The documents existed and carried real numbers. Matching the lot on your vial to the lot on the certificate is the check that does the work.
Is GMP for a bulk peptide the same as GMP for a medicine?
No. The cGMP rules in Part 211 cover drug products, defined in the regulations as finished dosage forms. Bulk peptide is an active pharmaceutical ingredient, and the standard for that is ICH Q7, a guidance rather than a regulation, and it states that it is not binding on FDA or the public.
Can I look up whether a manufacturer is real?
Partly. FDA publishes the Drug Establishments Current Registration Site, updated each business day, listing establishments that make or process drugs distributed in the United States. Registration is a filing requirement, and 21 CFR 207.77 says it does not denote approval of the establishment or the drug.
Is compounded peptide from a clinic pharmaceutical grade?
That is a different market with different rules. Outsourcing facilities registered under section 503B do operate under current good manufacturing practice. That is the one corner of the peptide world where the idea behind the phrase maps onto a real regulated system. It says nothing about a research vial bought online.
Is pharmaceutical grade the same as medical grade?
Neither is a drug quality standard. "Medical grade" does appear four times in Title 21, and in every case it describes what a device component is made from, such as silicone elastomer or acrylic adhesive. It has no meaning applied to a peptide.
Sources
- Electronic Code of Federal Regulations, full-text search of Title 21, run October 21, 2026 via the eCFR search API at ecfr.gov. Tier: queried at source. Exact-phrase counts from
meta.total_count, scoped withhierarchy[title]=21: "current good manufacturing practice" 1,354; "United States Pharmacopeia" 59; "official compendium" 23; "medical grade" 4; "pharmaceutical grade" 0; "research grade" 0. The "current good manufacturing practice" query was run as a control before the zero results were trusted, because an endpoint that returns nothing for every query would produce the same zero. Sample citations returned for "medical grade" were 21 CFR 888.3170 and 888.3810, both polymer joint prostheses described as made of medical grade silicone elastomer, and 21 CFR 358.303, a pad coated with medical grade acrylic adhesive. Counts are of sections matched by the search index and may differ slightly from a manual count of textual occurrences. ↩1 ↩2 ↩3 ↩4 - Federal Food, Drug, and Cosmetic Act, section 501, codified at 21 U.S.C. 351, Adulterated drugs and devices. Tier: read at source via the Legal Information Institute's reproduction of the US Code at law.cornell.edu; the Office of Law Revision Counsel text at uscode.house.gov was not opened. Subsection (b) covers drugs represented as a substance whose name is recognized in an official compendium, deeming them adulterated where "its strength differs from, or its quality or purity falls below, the standard set forth in such compendium," judged by the compendium's own tests or assays, with a proviso that a drug is not adulterated on this basis where the difference is "plainly stated on its label." Where compendial tests are absent or inadequate in the Secretary's judgment, the Secretary notifies the revising body and issues tests by regulation if it does not act. Paragraph (a)(2)(B) is the separate current good manufacturing practice provision. ↩1 ↩2 ↩3 ↩4
- 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals. Tier: structure read at source via the eCFR versioner API at ecfr.gov, title 21, part 211. Eleven subparts: A General Provisions, B Organization and Personnel, C Buildings and Facilities, D Equipment, E Control of Components and Drug Product Containers and Closures, F Production and Process Controls, G Packaging and Labeling Control, H Holding and Distribution, I Laboratory Controls, J Records and Reports, K Returned and Salvaged Drug Products. Sixty sections in total, counted from the structure response. ↩1 ↩2
- International Council for Harmonisation, Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients: Guidance for Industry. US Food and Drug Administration, CDER and CBER, September 2016, revision 1. hhs.gov. Tier: read at source as the published PDF. Replaces Q7A; endorsed by the ICH Steering Committee at Step 4 in November 2000. Carries "Contains Nonbinding Recommendations" on every page, states that it "represents the current thinking of the Food and Drug Administration," and that it "does not establish any rights for any person and is not binding on FDA or the public." Section 1.1 gives the objective as recommendations on good manufacturing practice for APIs under an appropriate quality management system, to help ensure APIs meet the quality and purity characteristics they are represented to have. Section 1.3 applies it to APIs for use in human drug products, made by chemical synthesis, extraction, cell culture or fermentation, recovery from natural sources, or a combination, and excludes medical gases, bulk-packaged drug products and radiopharmaceuticals. It asks a company to designate and document where API production begins, which for a synthetic process is the point at which API starting materials enter, and states that "This GMP guidance does not apply to steps prior to the introduction of the defined API starting material." ↩1 ↩2 ↩3 ↩4
- United States Pharmacopeia, Peptide Standards. usp.org/biologics/peptides. Tier: read at source; the page carries no visible date. Sixteen peptide families are listed: bivalirudin, calcitonin salmon, corticotropin, cosyntropin, desmopressin, eptifibatide, exenatide, glucagon, gonadorelin, leuprolide, octreotide, oxytocin, protamine sulfate, teriparatide, triptorelin and vasopressin. Gonadorelin and protamine sulfate appear as family headings with no member items shown. USP describes the families as comprising peptide API reference standards, related impurity reference standards and analytical reference materials, supported by "clear documentary standards with validated test methods, acceptance criteria." The page does not state which of these families has a published USP-NF monograph as distinct from a reference standard, so this page does not claim a monograph exists for each of the sixteen. ↩1 ↩2
- Peptide Decoding vendor pricing master, generated October 21, 2026. peptidedecoding.com/prices. Our own data, computed for this page, counting one priced product at one seller as a listing. The master holds 14,492 listings across 206 sellers and 192 distinct compound values. Compound names were normalized by lowercasing and stripping non-alphanumeric characters, then matched against the sixteen USP peptide families; a match required the normalized compound to equal a family name or to begin with one, which rejected a substring false positive where "nad" matches inside "gonadorelin." Four families matched, across four compound records: Gonadorelin, Oxytocin, Teriparatide and Triptorelin. Those records carry 176 listings, and three further oxytocin rows sat in the unassigned pool, bringing the total to 179. A separate scan of product titles, compound fields and review notes found the phrase "pharmaceutical grade" zero times, which reflects that the master captures prices and product names rather than marketing copy, so it is not evidence about how often sellers use the phrase. Figures are from the October 21, 2026 export. ↩1
- 21 CFR 211.22, Responsibilities of quality control unit. Tier: read at source via the Legal Information Institute at law.cornell.edu. Quoted: the unit shall have "the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products"; "the authority to review production records to assure that no errors have occurred" and where errors occurred "that they have been fully investigated"; "Adequate laboratory facilities for the testing and approval (or rejection) of components" shall be available to the unit; and responsibilities and procedures "shall be in writing" and "such written procedures shall be followed." The section also covers approval or rejection of products made under contract by another company, and approval or rejection of procedures and specifications affecting identity, strength, quality and purity. ↩1 ↩2
- 21 CFR 210.3(b)(4), Definitions. Tier: read at source via the Legal Information Institute at law.cornell.edu. "Drug product means a finished dosage form, for example, tablet, capsule, solution, etc., that contains an active drug ingredient generally, but not necessarily, in association with inactive ingredients," extending also to a finished dosage form without an active ingredient intended as a placebo. Related definitions read at the same time: active ingredient at (b)(7), component at (b)(3), inactive ingredient at (b)(8). The scope provision at 21 CFR 211.1(a) states that the part contains "the minimum current good manufacturing practice for preparation of drug products" for administration to humans or animals, and does not itself mention active pharmaceutical ingredients or bulk drug substances. ↩1
- US Food and Drug Administration, Drug Establishments Current Registration Site. fda.gov. Tier: read at source; the page carries no visible publication date. Publishes currently registered establishments that make or process drugs distributed in the United States or marketed for import, with a registration search plus annual registration status and excluded status download files. Updated each business day. Establishments must register within five days of beginning operations and renew annually between October 1 and December 31. Registrations are removed where FDA inactivates them through a compliance case or enforcement action, or where they expire, are deregistered or are dropped. The database excludes human drug compounding outsourcing facilities unless they also registered under other business operations, and excludes wholesale distributors and third-party logistics providers. The page does not itself state what registration does or does not imply, which is why the legal-status provision is cited separately at note 10. ↩1
- 21 CFR 207.77, What legal status is conferred by registration and listing? Tier: read at source via the Legal Information Institute at law.cornell.edu. Paragraph (a) states that "Registration of an establishment or listing of a drug does not denote approval of the establishment, the drug"; paragraph (b) states that "assignment of an NDC does not denote approval of the establishment or the drug." Both are quoted here as excerpts of longer sentences. ↩1
- US Food and Drug Administration, Center for Drug Evaluation and Research. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry. May 2021. fda.gov. Tier: full document read at source as the FDA PDF; the landing page was also opened and records the guidance as final, issued May 2021 by CDER under docket FDA-2017-D-5767, prepared by the Office of Generic Drugs. The document carries "Contains Nonbinding Recommendations" on every page, so it states FDA's current thinking and is not itself a binding rule. Scope is five peptides whose reference products are of recombinant DNA origin: glucagon, liraglutide, nesiritide, teriparatide and teduglutide. Quoted: applicants "should identify each peptide-related impurity that is 0.10 percent of the drug substance or greater," with impurities between 0.10% and 0.5% requiring structural characterization; a new specified peptide-related impurity absent from the reference listed drug should be "no more than 0.5 percent of the drug substance," above which an ANDA may not be the appropriate pathway; a new impurity above 0.5% "could raise concerns about the potential risk of immunogenicity"; peptide-related impurities carry "the potential for differences in immunogenicity" relative to the reference product. For impurities present in both products, the generic's level should be the same as or lower than the reference. Justification data should address MHC affinity and T-cell epitopes, aggregation propensity and innate immune stimulation. UHPLC-HRMS is recommended for detection and characterization. These thresholds govern generic applications for these five peptides and are used on this page as the published drug-quality benchmark, not as a rule that applies to research chemical sales. ↩1 ↩2 ↩3 ↩4 ↩5
- 21 CFR 201.128, Meaning of "intended uses". Tier: read at source via the Legal Information Institute at law.cornell.edu. Intended use refers to "the objective intent of the persons legally responsible for the labeling of an article," shown by "expressions, the design or composition of the article," the circumstances of distribution, and "labeling claims, advertising matter, or oral or written statements" by those persons or their representatives. The section carries a proviso that a firm is not treated as intending an unapproved new use for an approved drug solely because it knows health care providers are prescribing it that way. The page cites an amendment at 86 FR 41401, August 2, 2021; no fuller amendment history was shown. ↩1
- Peptide Decoding vendor testing audit, state as of October 21, 2026. peptidedecoding.com/vendors. Our own data. 206 stores tracked, 183 carrying a score, 23 meeting all five criteria. The five are: the store names its testing laboratory, a published certificate can be matched to a lot number, HPLC is named as the purity method, mass spectrometry is named for identity, and the testing is independent. Scoring rule set October 21, 2026: a criterion is met only where the store shows something a reader can check, being a lot number, a dated certificate, or a method named on a document, and a claim alone does not satisfy it. Stores whose pages could not be read are recorded as not audited rather than as showing nothing, after an earlier pass understated several stores by scoring sign-in walls. The eight-products-one-lot-number example is a single store in that audit; the store is not named here under our rule against naming sellers in editorial copy. Counts move as stores are added and re-read. ↩1 ↩2 ↩3 ↩4